Patents Assigned to Cephalon, Inc.
  • Liquid Formulations Of Bendamustine
    Publication number: 20120129904
    Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 24, 2012
    Applicant: CEPHALON, INC.
    Inventors: Anthony S. Drager, Rachel Y. LaBell, Piyush R. Patel
  • Modafinil modified release pharmaceutical compositions
    Patent number: 8153159
    Abstract: Pharmaceutical compositions comprising modafinil. The pharmaceutical compositions can have a release profile which is different than that of traditional pharmaceutical compositions of modafinil.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: April 10, 2012
    Assignee: Cephalon, Inc.
    Inventors: Alpa Parikh, Piyush Patel
  • Tricyclic aromatic and bis-phenyl sulfinyl derivatives
    Patent number: 8153667
    Abstract: The present invention provides compounds of the structure: wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: April 10, 2012
    Assignee: Cephalon, Inc.
    Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Rabindranath Tripathy
  • SURFACE-TREATED MODAFINIL PARTICLES
    Publication number: 20120082726
    Abstract: The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof.
    Type: Application
    Filed: December 13, 2011
    Publication date: April 5, 2012
    Applicant: CEPHALON, INC.
    Inventors: Salah U. AHMED, Muhammed A. HOSSAIN, Pruthvi R. KATIKANENI, Zhijun JIANG
  • Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
    Patent number: 8148391
    Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: April 3, 2012
    Assignee: Cephalon, Inc.
    Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-Qiang Liu, Eugen Florin Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
  • COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES
    Publication number: 20120076757
    Abstract: The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 29, 2012
    Applicant: Cephalon, Inc.
    Inventors: Steve L. Durfee, Gary Thurman
  • Combination Therapy for the Treatment of Multiple Myeloma
    Publication number: 20120071445
    Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 22, 2012
    Applicant: Cephalon, Inc.
    Inventor: James R. Berenson
  • NOVEL SOLID FORMS OF BENDAMUSTINE HYDROCHLORIDE
    Publication number: 20120071532
    Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 22, 2012
    Applicant: CEPHALON, INC.
    Inventors: Martin Ian Cooper, Laurent D. Courvoisier, Mark Eddleston, Robert E. McKean
  • Effervescent oral fentanyl dosage form and methods of administering fentanyl
    Patent number: 8119158
    Abstract: Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: February 21, 2012
    Assignee: Cephalon, Inc.
    Inventors: Derek Moe, Vikas Agarwal, Walib Habib
  • Proteasome Inhibitors and Methods of Using the Same
    Publication number: 20120041196
    Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
    Type: Application
    Filed: September 30, 2011
    Publication date: February 16, 2012
    Applicant: CEPHALON, INC.
    Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassará, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
  • Lyophilization Cakes of Proteasome Inhibitors
    Publication number: 20120035133
    Abstract: Lyophilized cakes of proteasome inhibitors are described, as well as methods for their production and use.
    Type: Application
    Filed: September 29, 2011
    Publication date: February 9, 2012
    Applicants: CEPHALON FRANCE, CEPHALON, INC.
    Inventors: Denis Bricout, Helene Cambourieux, Michael L. Cappola, Nicole Frati, Piyush R. Patel
  • PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
    Publication number: 20120028919
    Abstract: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: June 15, 2011
    Publication date: February 2, 2012
    Applicant: CEPHALON, INC.
    Inventors: Henry J. Breslin, Sankar Chatterjee, James L. Diebold, Bruce D. Dorsey, Derek D. Dunn, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Rachael Hunter, Kurt A. Josef, Joseph Lisko, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Babu G. Sundar, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Linda Weinberg, Gregory J. Wells, Craig A. Zificsak
  • Generally linear effervescent oral fentanyl dosage form and methods of administering
    Patent number: 8092832
    Abstract: Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: January 10, 2012
    Assignee: Cephalon, Inc.
    Inventors: Derek Moe, Vikas Agarwal, Walib Habib
  • Novel Fused Pyrrolocarbazoles
    Publication number: 20120004253
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 5, 2012
    Applicant: CEPHALON, INC.
    Inventors: Nadine C. Becknell, Peter D. Brown, James L. Diebold, Diane E. Gingrich, Robert L. Hudkins, Reddeppareddy Dandu, Bruce A. Ruggeri, Ming Tao, Theodore L. Underiner, Allison L. Zulli
  • Substituted Pyridazine Derivatives
    Publication number: 20120004231
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: CEPHALON, INC.
    Inventors: Robert L. Hudkins, Lars J.S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht
  • Fused pyrrolocarbazoles
    Patent number: 8084472
    Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: December 27, 2011
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Reddeppareddy Dandu, Ming Tao, Theodore L. Underiner, Allison L. Zulli
  • Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
    Patent number: 8080561
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: December 20, 2011
    Assignee: Cephalon, Inc.
    Inventors: Bruce D. Dorsey, Jay P. Theroff, Linda Weinberg, Craig A. Zificsak
  • Forms of bendamustine free base
    Patent number: 8076366
    Abstract: Novel polymorphic forms of bendamustine free base are described, including amorphous bendamustine free base, six anhydrous crystalline forms, four hydrate forms, and five solvate forms, with methods of their preparation and use also being described.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: December 13, 2011
    Assignee: Cephalon, Inc.
    Inventors: Laurent D. Courvoisier, Mark Eddleston, R. Curtis Haltiwanger, Robert E. McKean
  • Crystalline forms of a pharmaceutical compound
    Patent number: 8076320
    Abstract: Described are crystalline forms of the pharmaceutical compound “[9S-(9?,10?,12?)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3?,2?,1?-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester”, as well as methods for their use and preparation.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: December 13, 2011
    Assignee: Cephalon, Inc.
    Inventors: Michael Harold Rock, Heidi Lopez De Diego, Kim Lasse Christensen, Ole Nielsen, Anders Buur, Mark Howells
  • Substituted pyridazine derivatives
    Patent number: 8076331
    Abstract: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: December 13, 2011
    Assignee: Cephalon, Inc.
    Inventors: Robert L. Hudkins, Lars J. S. Knutsen, Catherine P. Prouty, Babu G. Sundar, Kevin J. Wells-Knecht